The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: SLC25A13 (Citrin) — Human Mitochondrial Aspartate/Glutamate Carrier 2

1. Gene and Protein Identity

SLC25A13 (Solute Carrier Family 25 Member 13; UniProt Q9UJS0) encodes the mitochondrial aspartate/glutamate carrier isoform 2 (AGC2), commonly known as citrin. It is also referred to as ARALAR2 or calcium-binding mitochondrial carrier protein Aralar2 (palmieri2013themitochondrialtransporter pages 15-16, tavoulari2024distinctrolesfor pages 1-2). Citrin belongs to the SLC25 mitochondrial carrier family (TC 2.A.29), which comprises 53 members in humans that transport a wide variety of solutes across the inner mitochondrial membrane (kunji2025thepeculiarproperties pages 3-4, ruprecht2020theslc25mitochondrial pages 1-2). Citrin is one of two mammalian isoforms of aspartate/glutamate carriers, the other being aralar (AGC1/SLC25A12), which shares 78% sequence identity with citrin but differs markedly in tissue expression (gonzalezmoreno2023exogenousaralarslc25a12can pages 2-3).

The following table summarizes the key properties of SLC25A13/citrin:

Table: This table summarizes the key molecular, cellular, metabolic, and disease-related properties of human SLC25A13/citrin. It is useful as a quick reference linking transporter function and structure to citrin deficiency phenotypes.

2. Primary Transport Function and Substrate Specificity

Citrin functions as an electrogenic aspartate/glutamate antiporter embedded in the inner mitochondrial membrane. Its primary transport activity is the export of aspartate anions from the mitochondrial matrix into the cytosol, coupled with the import of cytosolic glutamate anions plus a proton (H⁺) into the matrix (palmieri2013themitochondrialtransporter pages 15-16, tavoulari2024distinctrolesfor pages 1-2, ruprecht2020theslc25mitochondrial pages 1-2). This co-transport of glutamate with a proton is driven by the mitochondrial proton motive force, which renders the shuttle practically unidirectional toward oxidation of cytosolic NADH, maintaining the cytosolic NAD⁺/NADH pool in a more oxidized state than the mitochondrial matrix pool (kunji2025thepeculiarproperties pages 3-4).

The electrogenic nature of this exchange—where aspartate carries a net negative charge of -1 and glutamate plus a proton is effectively neutral—means the transport is driven forward by the mitochondrial membrane potential (broeks2021inborndisordersof pages 6-10). This thermodynamic coupling ensures a robust unidirectional flow of aspartate out of mitochondria, which is critical for hepatocyte metabolism.

3. Protein Structure and Domain Architecture

Citrin possesses an unusual three-domain architecture that distinguishes it from most other SLC25 family members (tavoulari2024distinctrolesfor pages 1-2, lacabanne2025currentunderstandingof pages 3-4):

N-terminal calcium-binding domain: This domain contains eight EF-hand motifs, of which only EF-hand 2 possesses a functional calcium-binding site. EF-hands 4–8 do not bind calcium and instead form a dimerization interface (lacabanne2025currentunderstandingof pages 3-4). Importantly, recent work by Tavoulari et al. (2024) has demonstrated that calcium binding to EF-hand 2 is not required for transport regulation. A mutant in which the calcium-binding site was completely abolished (quadruple alanine substitution D66A/T68A/D70A/E77A) retained full transport activity and normal mitochondrial localization (tavoulari2024distinctrolesfor pages 11-12, tavoulari2024distinctrolesfor pages 7-9). The calcium-binding site is now proposed to be an evolutionary remnant (tavoulari2024distinctrolesfor pages 11-12). However, the N-terminal domain plays a critical role in mitochondrial targeting and localization, and pathogenic mutations in this region often cause localization defects rather than transport defects (tavoulari2024distinctrolesfor pages 9-11).

Carrier domain: This is the substrate-transporting module, consisting of three homologous sequence repeats, each containing two transmembrane α-helices connected by a loop harboring a short matrix helix, forming a six-helical bundle with a central water-filled cavity that serves as the substrate translocation pathway (lacabanne2025currentunderstandingof pages 3-4, ruprecht2020theslc25mitochondrial pages 2-3). The carrier operates through an alternating access mechanism, interconverting between a matrix-open (m-state) and a cytoplasmic-open (c-state) conformation. This switching is achieved through coordinated disruption and reformation of salt-bridge networks on either side of the carrier. Three gate elements on the cytoplasmic side and three core elements on the matrix side open and close in alternating fashion to permit substrate binding and translocation (tavoulari2024distinctrolesfor pages 1-2, lacabanne2025currentunderstandingof pages 4-6).

C-terminal amphipathic helix: This short domain contributes to the overall structural integrity and membrane association of the protein (tavoulari2024distinctrolesfor pages 1-2, lacabanne2025currentunderstandingof pages 3-4).

Citrin is unique among SLC25 carriers in that it forms structural homodimers through its N-terminal domains, although the two carrier domains within the dimer appear to function independently rather than cooperatively (tavoulari2024distinctrolesfor pages 11-12, tavoulari2024distinctrolesfor pages 1-2). The full-length atomic structure of citrin has not yet been experimentally resolved, though structural models have been proposed based on domain structures and homology modeling with the ADP/ATP carrier (lacabanne2025currentunderstandingof pages 3-4).

4. Subcellular Localization and Tissue Expression

Citrin is localized to the inner mitochondrial membrane, where it mediates metabolite exchange between the mitochondrial matrix and the intermembrane space/cytosol (lacabanne2025currentunderstandingof pages 3-4, gonzalezmoreno2023exogenousaralarslc25a12can pages 1-2).

The tissue expression pattern of citrin is distinctive and has profound implications for disease. In human liver, citrin is the sole or overwhelmingly dominant AGC isoform, with quantitative proteomics revealing a citrin-to-aralar molar ratio of approximately 397:1 (gonzalezmoreno2023exogenousaralarslc25a12can pages 1-2, gonzalezmoreno2023exogenousaralarslc25a12can pages 8-9). This stands in stark contrast to mouse liver, where the ratio is only approximately 8:1, which explains why citrin-knockout mice display a much milder phenotype than human patients with citrin deficiency (gonzalezmoreno2023exogenousaralarslc25a12can pages 8-9, gonzalezmoreno2023exogenousaralarslc25a12can pages 1-2). Beyond liver, citrin is abundantly expressed in intestinal epithelium and is also present in kidney and heart (where it coexists with aralar) (broeks2021inborndisordersof pages 6-10, gonzalezmoreno2023exogenousaralarslc25a12can pages 2-3, ahmed2024theroleof pages 11-13). In the adult brain, citrin expression is extremely low and restricted to discrete neuronal clusters, including the deep cerebellar nuclei, vestibular nuclei, reticular nuclei of the thalamus, reticular tegmental nuclei of the pons, and red magnocellular nuclei (contreras2010lowlevelsof pages 1-2, contreras2010lowlevelsof pages 4-6). No citrin expression is detected in brain glial cells (contreras2010lowlevelsof pages 4-6).

5. Metabolic Pathways and Biochemical Roles

5.1 The Malate-Aspartate Shuttle (MAS)

Citrin is the principal component of the malate-aspartate shuttle in hepatocytes, which is the primary mechanism for transferring reducing equivalents (NADH) produced in the cytosol during glycolysis, lactate oxidation, and ethanol oxidation into mitochondria for oxidative phosphorylation (holecek2023aspartateglutamatecarrier2 pages 1-2, gonzalezmoreno2023exogenousaralarslc25a12can pages 1-2). In the MAS, cytosolic NADH reduces oxaloacetate to malate (via cytosolic malate dehydrogenase), malate enters the mitochondrial matrix via the oxoglutarate carrier, and is re-oxidized to oxaloacetate (via mitochondrial malate dehydrogenase), generating mitochondrial NADH. Oxaloacetate is then transaminated to aspartate (via mitochondrial GOT2), and citrin exports aspartate to the cytosol in exchange for glutamate. In the cytosol, aspartate is transaminated back to oxaloacetate, regenerating NAD⁺ (holecek2023aspartateglutamatecarrier2 pages 1-2, broeks2021inborndisordersof pages 6-10). This shuttle is essential for maintaining the cytosolic NAD⁺/NADH redox balance, mitochondrial respiration, and ATP synthesis (holecek2023aspartateglutamatecarrier2 pages 1-2).

5.2 The Urea Cycle

Citrin plays a critical role in hepatic ureagenesis by exporting aspartate from mitochondria to the cytosol, where it serves as the substrate for argininosuccinate synthetase (ASS1), the enzyme that condenses aspartate with citrulline to form argininosuccinate (holecek2023aspartateglutamatecarrier2 pages 1-2, cunningham202020000picometersunder pages 4-5). Aspartate provides one of the two nitrogen atoms in the urea molecule (the other being ammonia). When citrin is deficient, cytosolic aspartate availability is reduced, impairing the urea cycle and leading to hyperammonemia and citrullinemia (palmieri2013themitochondrialtransporter pages 15-16, gonzalezmoreno2023exogenousaralarslc25a12can pages 1-2).

5.3 Gluconeogenesis

Through its role in the MAS, citrin supports gluconeogenesis by facilitating the transfer of aspartate to the cytosol, where it can be transaminated to oxaloacetate—the starting substrate for the gluconeogenic pathway. This linkage is particularly important during starvation, exercise, and amino acid catabolism, when glucagon and catecholamines stimulate both the urea cycle and gluconeogenesis simultaneously (holecek2023aspartateglutamatecarrier2 pages 2-4, lacabanne2025currentunderstandingof pages 3-4).

5.4 Nucleotide and Protein Synthesis

The cytosolic aspartate supplied by citrin also serves as a precursor for de novo purine and pyrimidine nucleotide biosynthesis and for protein synthesis (palmieri2013themitochondrialtransporter pages 15-16, gonzalezmoreno2023exogenousaralarslc25a12can pages 1-2, owusuansah2023nagscps1and pages 2-4). In cancer biology, citrin-mediated aspartate export has been shown to promote pyrimidine biosynthesis via the CAD complex, supporting tumor cell proliferation (owusuansah2023nagscps1and pages 2-4, owusuansah2023nagscps1and pages 1-2).

5.5 Redox Regulation and Energy Metabolism

The fundamental consequence of citrin function is the maintenance of the cytosolic NAD⁺/NADH ratio, which is essential for glycolysis, gluconeogenesis, and fatty acid β-oxidation. When citrin is absent or dysfunctional, the cytosolic NADH/NAD⁺ ratio becomes elevated, suppressing glycolysis and gluconeogenesis, impairing fatty acid oxidation, and creating a cellular energy deficit (palmieri2013themitochondrialtransporter pages 15-16, nuyttens2025acrucialrole pages 2-3, nuyttens2025acrucialrole pages 9-11). Recent work using Slc25a13⁻/⁻ mice in the context of TNF-induced systemic inflammatory response syndrome (SIRS) has demonstrated that citrin deficiency exacerbates metabolic dysfunction, causing severe hyperlactatemia, hepatic lipid accumulation, and increased lethality through disrupted NAD⁺ regeneration (nuyttens2025acrucialrole pages 2-3, nuyttens2025acrucialrole pages 11-12, nuyttens2025acrucialrole pages 9-11).

6. Calcium Regulation: A Revised Understanding

A long-standing model held that citrin's transport activity was stimulated by calcium binding to its N-terminal EF-hand domain (goyani2024calciumsignalingin pages 4-6, holecek2023aspartateglutamatecarrier2 pages 2-4). However, landmark recent studies have fundamentally revised this view. Tavoulari et al. (2024) demonstrated, using purified citrin reconstituted in liposomes, that transport activity is not regulated by calcium in vitro (tavoulari2024distinctrolesfor pages 1-2, tavoulari2024distinctrolesfor pages 7-9). Complete abolition of the calcium-binding site had no effect on transport function, mitochondrial localization, or dimerization (tavoulari2024distinctrolesfor pages 7-9). The calcium-binding site in EF-hand 2 is described as non-canonical and pre-formed, and is now proposed to be an evolutionary remnant (tavoulari2024distinctrolesfor pages 11-12). This finding, confirmed by Lacabanne et al. (2025), suggests that calcium does not play a direct role in citrin deficiency pathogenesis and that earlier observations of calcium-dependent activation may have been indirect or related to other regulatory mechanisms (lacabanne2025currentunderstandingof pages 4-6, kunji2025thepeculiarproperties pages 3-4).

7. Disease Associations: Citrin Deficiency

Biallelic loss-of-function mutations in SLC25A13 cause citrin deficiency (CD), an autosomal recessive metabolic disorder with three recognized age-dependent phenotypes (vukovic2024thetherapeuticlandscape pages 1-2, komatsu2023citrindeficiencyclinical pages 1-2, kido2024clinicallandscapeof pages 1-2):

NICCD (Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency): Presents in neonates/infants with prolonged jaundice, intrahepatic cholestasis, hepatomegaly, fatty liver, low birth weight, hypoproteinemia, coagulopathy, elevated alpha-fetoprotein, galactosemia, citrullinemia, and hypoglycemia. NICCD typically resolves spontaneously by one year of age, though severe cases may progress to liver failure (vukovic2024thetherapeuticlandscape pages 1-2, komatsu2023citrindeficiencyclinical pages 1-2, kido2022clinicalmanifestationand pages 1-7).

FTTDCD (Failure to Thrive and Dyslipidemia Caused by Citrin Deficiency): A post-NICCD intermediate phenotype characterized by growth impairment, recurrent hypoglycemia, fatigue, hypertriglyceridemia, pancreatitis, and non-obese non-alcoholic fatty liver disease (vukovic2024thetherapeuticlandscape pages 1-2, komatsu2023citrindeficiencyclinical pages 1-2, hayasaka2024pathogenesisandmanagement pages 2-4).

CTLN2/AACD (Adult-Onset Type II Citrullinemia / Adolescent and Adult Citrin Deficiency): The most severe form, developing in approximately 5% of citrin-deficient individuals (typically ages 10–70), characterized by sudden attacks of hyperammonemia, nocturnal encephalopathy, neuropsychological abnormalities including disorientation, abnormal behavior, convulsions, and coma (komatsu2023citrindeficiencyclinical pages 1-2, hayasaka2024pathogenesisandmanagement pages 2-4, kido2022clinicalmanifestationand pages 7-11). Complications include liver cirrhosis and hepatocellular carcinoma (kido2022clinicalmanifestationand pages 7-11).

CD patients characteristically exhibit peculiar dietary preferences, disliking high-carbohydrate foods while preferring fat- and protein-rich foods, which represents a compensatory metabolic adaptation (komatsu2023citrindeficiencyclinical pages 1-2). The disease is highly prevalent in East Asian populations but is now recognized as a pan-ethnic, global condition (kido2024clinicallandscapeof pages 1-2, haberle2024citrindeficiency—theeast‐side pages 1-2). A nationwide Japanese study identified 68 genetic variants across 345 patients, with the c.852_855del variant being the most prevalent, found in 42% of NICCD/post-NICCD cases and 49% of AACD patients (kido2024clinicallandscapeof pages 1-2).

Current treatment includes dietary management (low-carbohydrate, high-fat/protein diet), medium-chain triglyceride (MCT) supplementation, and in severe cases, liver transplantation as the sole curative option (vukovic2024thetherapeuticlandscape pages 1-2, hayasaka2024pathogenesisandmanagement pages 2-4). Gene therapy approaches are under development, including mRNA-based strategies (vukovic2024thetherapeuticlandscape pages 1-2).

8. Relationship to Aralar (AGC1/SLC25A12)

Citrin and aralar share 78% sequence identity and perform the same fundamental transport function (aspartate/glutamate exchange), but differ critically in tissue distribution (gonzalezmoreno2023exogenousaralarslc25a12can pages 2-3). Aralar is predominantly expressed in brain, skeletal muscle, and heart, while citrin dominates in liver and intestine (gonzalezmoreno2023exogenousaralarslc25a12can pages 2-3, pardo2022agc1deficiencypathology pages 2-4). In human liver, aralar is virtually absent (citrin:aralar ratio ~400:1), making citrin absolutely indispensable for hepatic metabolism (gonzalezmoreno2023exogenousaralarslc25a12can pages 1-2). Importantly, González-Moreno et al. (2023) demonstrated that exogenous aralar can functionally replace citrin in liver, restoring MAS activity and normalizing NADH/NAD⁺ ratios in citrin-deficient hepatocytes, suggesting a potential therapeutic strategy (gonzalezmoreno2023exogenousaralarslc25a12can pages 8-9, gonzalezmoreno2023exogenousaralarslc25a12can pages 9-10).

9. Role in Cancer

Citrin is upregulated in multiple cancer types, including glioblastoma, glioma, stomach adenocarcinoma, and lung adenocarcinoma (1.4- to 4-fold higher expression compared to matched normal tissues) (owusuansah2023nagscps1and pages 2-4). In cancer cells, citrin supports metabolic reprogramming by: (1) maintaining NAD⁺/NADH pools to sustain glycolysis and oxidative phosphorylation; (2) increasing cytosolic aspartate availability for pyrimidine biosynthesis via the CAD complex; and (3) promoting cancer cell migration and invasion through regulation of energy-consuming processes and MMP-9 expression (rabinovich2020themitochondrialcarrier pages 2-4, rabinovich2020themitochondrialcarrier pages 1-2, rabinovich2020themitochondrialcarrier pages 4-5). Citrin overexpression increases lactate production, glycolytic intermediates, and oxygen consumption rates, while citrin depletion restricts these processes (rabinovich2020themitochondrialcarrier pages 4-5). Citrin gene copy number correlates with mRNA expression in several tumor types (owusuansah2023nagscps1and pages 1-2). These findings suggest citrin may represent a novel therapeutic target in cancer (rabinovich2020themitochondrialcarrier pages 2-4, gao2024cancertherapeuticpotential pages 4-6).

10. Conclusions

SLC25A13/citrin is a mitochondrial inner membrane aspartate/glutamate antiporter of central importance to hepatic metabolism. It exports aspartate from the mitochondrial matrix in exchange for glutamate plus a proton, thereby serving as the key component of the malate-aspartate shuttle in liver. This transport activity is essential for maintaining cytosolic NAD⁺/NADH redox balance, fueling the urea cycle, supporting gluconeogenesis, and providing aspartate for nucleotide and protein biosynthesis. Structurally, citrin is distinguished by its three-domain architecture and homodimeric organization, with recent work overturning the long-held view that calcium regulates its transport activity. Loss-of-function mutations cause citrin deficiency, a clinically complex metabolic disorder with age-dependent hepatic and neurological manifestations, while citrin upregulation in tumors supports cancer cell metabolic reprogramming and proliferation.

References

1. (palmieri2013themitochondrialtransporter pages 15-16): Ferdinando Palmieri. The mitochondrial transporter family slc25: identification, properties and physiopathology. Molecular aspects of medicine, 34 2-3:465-84, Apr 2013. URL: https://doi.org/10.1016/j.mam.2012.05.005, doi:10.1016/j.mam.2012.05.005. This article has 740 citations and is from a highest quality peer-reviewed journal.

2. (tavoulari2024distinctrolesfor pages 1-2): Sotiria Tavoulari, Denis Lacabanne, Gonçalo C. Pereira, Chancievan Thangaratnarajah, Martin S. King, Jiuya He, Suvagata R. Chowdhury, Lisa Tilokani, Shane M. Palmer, Julien Prudent, John E. Walker, and Edmund R.S. Kunji. Distinct roles for the domains of the mitochondrial aspartate/glutamate carrier citrin in organellar localization and substrate transport. Dec 2024. URL: https://doi.org/10.1016/j.molmet.2024.102047, doi:10.1016/j.molmet.2024.102047. This article has 12 citations and is from a domain leading peer-reviewed journal.

3. (kunji2025thepeculiarproperties pages 3-4): E. Kunji, Vasiliki Mavridou, Martin S King, Camila Cimadamore-Werthein, Stephany Jaiquel Baron, Scott A Jones, Alannah C. King, Roger J Springett, Deepak Chand, Shane M Palmer, Denis Lacabanne, Sotiria Tavoulari, and J. Ruprecht. The peculiar properties of mitochondrial carriers of the slc25 family. The Biochemical journal, Jul 2025. URL: https://doi.org/10.1042/bcj20253171, doi:10.1042/bcj20253171. This article has 14 citations.

4. (ruprecht2020theslc25mitochondrial pages 1-2): Jonathan J. Ruprecht and Edmund R.S. Kunji. The slc25 mitochondrial carrier family: structure and mechanism. Trends in Biochemical Sciences, 45:244-258, Mar 2020. URL: https://doi.org/10.1016/j.tibs.2019.11.001, doi:10.1016/j.tibs.2019.11.001. This article has 440 citations and is from a domain leading peer-reviewed journal.

5. (gonzalezmoreno2023exogenousaralarslc25a12can pages 2-3): Luis González-Moreno, Andrea Santamaría-Cano, Alberto Paradela, María Luz Martínez-Chantar, Miguel Á. Martín, Mercedes Pérez-Carreras, Alberto García-Picazo, Jesús Vázquez, Enrique Calvo, Gloria González-Aseguinolaza, Takeyori Saheki, Araceli del Arco, Jorgina Satrústegui, and Laura Contreras. Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver. Jun 2023. URL: https://doi.org/10.1016/j.ymgmr.2023.100967, doi:10.1016/j.ymgmr.2023.100967. This article has 9 citations.

6. (holecek2023aspartateglutamatecarrier2 pages 1-2): Milan Holeček. Aspartate-glutamate carrier 2 (citrin): a role in glucose and amino acid metabolism in the liver. BMB Reports, 56:385-391, Jun 2023. URL: https://doi.org/10.5483/bmbrep.2023-0052, doi:10.5483/bmbrep.2023-0052. This article has 5 citations and is from a peer-reviewed journal.

7. (vukovic2024thetherapeuticlandscape pages 1-2): Toni Vuković, Li Eon Kuek, Barbara Yu, Georgios Makris, and Johannes Häberle. The therapeutic landscape of citrin deficiency. Journal of Inherited Metabolic Disease, 47:1157-1174, Jul 2024. URL: https://doi.org/10.1002/jimd.12768, doi:10.1002/jimd.12768. This article has 14 citations and is from a peer-reviewed journal.

8. (kido2024clinicallandscapeof pages 1-2): Jun Kido, Georgios Makris, Saikat Santra, and Johannes Häberle. Clinical landscape of citrin deficiency: a global perspective on a multifaceted condition. Journal of Inherited Metabolic Disease, 47:1144-1156, Mar 2024. URL: https://doi.org/10.1002/jimd.12722, doi:10.1002/jimd.12722. This article has 30 citations and is from a peer-reviewed journal.

9. (lacabanne2025currentunderstandingof pages 3-4): Denis Lacabanne, Alice P. Sowton, Bosco Jose, Edmund R. S. Kunji, and Sotiria Tavoulari. Current understanding of pathogenic mechanisms and disease models of citrin deficiency. Journal of Inherited Metabolic Disease, Mar 2025. URL: https://doi.org/10.1002/jimd.70021, doi:10.1002/jimd.70021. This article has 7 citations and is from a peer-reviewed journal.

10. (gonzalezmoreno2023exogenousaralarslc25a12can pages 1-2): Luis González-Moreno, Andrea Santamaría-Cano, Alberto Paradela, María Luz Martínez-Chantar, Miguel Á. Martín, Mercedes Pérez-Carreras, Alberto García-Picazo, Jesús Vázquez, Enrique Calvo, Gloria González-Aseguinolaza, Takeyori Saheki, Araceli del Arco, Jorgina Satrústegui, and Laura Contreras. Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver. Jun 2023. URL: https://doi.org/10.1016/j.ymgmr.2023.100967, doi:10.1016/j.ymgmr.2023.100967. This article has 9 citations.

11. (contreras2010lowlevelsof pages 1-2): Laura Contreras, Almudena Urbieta, Keiko Kobayashi, Takeyori Saheki, and Jorgina Satrústegui. Low levels of citrin (slc25a13) expression in adult mouse brain restricted to neuronal clusters. Journal of Neuroscience Research, 88:1009-1016, Apr 2010. URL: https://doi.org/10.1002/jnr.22283, doi:10.1002/jnr.22283. This article has 24 citations and is from a peer-reviewed journal.

12. (broeks2021inborndisordersof pages 6-10): Melissa H. Broeks, Clara D. M. van Karnebeek, Ronald J. A. Wanders, Judith J. M. Jans, and Nanda M. Verhoeven‐Duif. Inborn disorders of the malate aspartate shuttle. Journal of Inherited Metabolic Disease, 44:792-808, May 2021. URL: https://doi.org/10.1002/jimd.12402, doi:10.1002/jimd.12402. This article has 93 citations and is from a peer-reviewed journal.

13. (lacabanne2025currentunderstandingof pages 4-6): Denis Lacabanne, Alice P. Sowton, Bosco Jose, Edmund R. S. Kunji, and Sotiria Tavoulari. Current understanding of pathogenic mechanisms and disease models of citrin deficiency. Journal of Inherited Metabolic Disease, Mar 2025. URL: https://doi.org/10.1002/jimd.70021, doi:10.1002/jimd.70021. This article has 7 citations and is from a peer-reviewed journal.

14. (holecek2023aspartateglutamatecarrier2 pages 2-4): Milan Holeček. Aspartate-glutamate carrier 2 (citrin): a role in glucose and amino acid metabolism in the liver. BMB Reports, 56:385-391, Jun 2023. URL: https://doi.org/10.5483/bmbrep.2023-0052, doi:10.5483/bmbrep.2023-0052. This article has 5 citations and is from a peer-reviewed journal.

15. (komatsu2023citrindeficiencyclinical pages 1-2): Michiharu Komatsu, Naoki Tanaka, Takefumi Kimura, and Masahide Yazaki. Citrin deficiency: clinical and nutritional features. Nutrients, 15:2284, May 2023. URL: https://doi.org/10.3390/nu15102284, doi:10.3390/nu15102284. This article has 19 citations.

16. (kido2022clinicalmanifestationand pages 7-11): Jun Kido, Johannes Häberle, Keishin Sugawara, Toju Tanaka, Masayoshi Nagao, Takaaki Sawada, Yoichi Wada, Chikahiko Numakura, Kei Murayama, Yoriko Watanabe, Kanako Kojima‐Ishii, Hideo Sasai, Kiyotaka Kosugiyama, and Kimitoshi Nakamura. Clinical manifestation and long‐term outcome of citrin deficiency: report from a nationwide study in japan. Journal of Inherited Metabolic Disease, 45:431-444, Feb 2022. URL: https://doi.org/10.1002/jimd.12483, doi:10.1002/jimd.12483. This article has 39 citations and is from a peer-reviewed journal.

17. (tavoulari2024distinctrolesfor pages 11-12): Sotiria Tavoulari, Denis Lacabanne, Gonçalo C. Pereira, Chancievan Thangaratnarajah, Martin S. King, Jiuya He, Suvagata R. Chowdhury, Lisa Tilokani, Shane M. Palmer, Julien Prudent, John E. Walker, and Edmund R.S. Kunji. Distinct roles for the domains of the mitochondrial aspartate/glutamate carrier citrin in organellar localization and substrate transport. Dec 2024. URL: https://doi.org/10.1016/j.molmet.2024.102047, doi:10.1016/j.molmet.2024.102047. This article has 12 citations and is from a domain leading peer-reviewed journal.

18. (tavoulari2024distinctrolesfor pages 7-9): Sotiria Tavoulari, Denis Lacabanne, Gonçalo C. Pereira, Chancievan Thangaratnarajah, Martin S. King, Jiuya He, Suvagata R. Chowdhury, Lisa Tilokani, Shane M. Palmer, Julien Prudent, John E. Walker, and Edmund R.S. Kunji. Distinct roles for the domains of the mitochondrial aspartate/glutamate carrier citrin in organellar localization and substrate transport. Dec 2024. URL: https://doi.org/10.1016/j.molmet.2024.102047, doi:10.1016/j.molmet.2024.102047. This article has 12 citations and is from a domain leading peer-reviewed journal.

19. (tavoulari2024distinctrolesfor pages 9-11): Sotiria Tavoulari, Denis Lacabanne, Gonçalo C. Pereira, Chancievan Thangaratnarajah, Martin S. King, Jiuya He, Suvagata R. Chowdhury, Lisa Tilokani, Shane M. Palmer, Julien Prudent, John E. Walker, and Edmund R.S. Kunji. Distinct roles for the domains of the mitochondrial aspartate/glutamate carrier citrin in organellar localization and substrate transport. Dec 2024. URL: https://doi.org/10.1016/j.molmet.2024.102047, doi:10.1016/j.molmet.2024.102047. This article has 12 citations and is from a domain leading peer-reviewed journal.

20. (ruprecht2020theslc25mitochondrial pages 2-3): Jonathan J. Ruprecht and Edmund R.S. Kunji. The slc25 mitochondrial carrier family: structure and mechanism. Trends in Biochemical Sciences, 45:244-258, Mar 2020. URL: https://doi.org/10.1016/j.tibs.2019.11.001, doi:10.1016/j.tibs.2019.11.001. This article has 440 citations and is from a domain leading peer-reviewed journal.

21. (gonzalezmoreno2023exogenousaralarslc25a12can pages 8-9): Luis González-Moreno, Andrea Santamaría-Cano, Alberto Paradela, María Luz Martínez-Chantar, Miguel Á. Martín, Mercedes Pérez-Carreras, Alberto García-Picazo, Jesús Vázquez, Enrique Calvo, Gloria González-Aseguinolaza, Takeyori Saheki, Araceli del Arco, Jorgina Satrústegui, and Laura Contreras. Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver. Jun 2023. URL: https://doi.org/10.1016/j.ymgmr.2023.100967, doi:10.1016/j.ymgmr.2023.100967. This article has 9 citations.

22. (ahmed2024theroleof pages 11-13): Amer Ahmed, Giorgia Natalia Iaconisi, Daria Di Molfetta, Vincenzo Coppola, Antonello Caponio, Ansu Singh, Aasia Bibi, Loredana Capobianco, Luigi Palmieri, Vincenza Dolce, and Giuseppe Fiermonte. The role of mitochondrial solute carriers slc25 in cancer metabolic reprogramming: current insights and future perspectives. International Journal of Molecular Sciences, 26:92, Dec 2024. URL: https://doi.org/10.3390/ijms26010092, doi:10.3390/ijms26010092. This article has 18 citations.

23. (contreras2010lowlevelsof pages 4-6): Laura Contreras, Almudena Urbieta, Keiko Kobayashi, Takeyori Saheki, and Jorgina Satrústegui. Low levels of citrin (slc25a13) expression in adult mouse brain restricted to neuronal clusters. Journal of Neuroscience Research, 88:1009-1016, Apr 2010. URL: https://doi.org/10.1002/jnr.22283, doi:10.1002/jnr.22283. This article has 24 citations and is from a peer-reviewed journal.

24. (cunningham202020000picometersunder pages 4-5): Corey N Cunningham and Jared Rutter. 20,000 picometers under the omm: diving into the vastness of mitochondrial metabolite transport. EMBO reports, Apr 2020. URL: https://doi.org/10.15252/embr.202050071, doi:10.15252/embr.202050071. This article has 48 citations and is from a highest quality peer-reviewed journal.

25. (owusuansah2023nagscps1and pages 2-4): Melissa Owusu-Ansah, Nikita Guptan, Dylon Alindogan, Michio Morizono, and Ljubica Caldovic. Nags, cps1, and slc25a13 (citrin) at the crossroads of arginine and pyrimidines metabolism in tumor cells. International Journal of Molecular Sciences, 24:6754, Apr 2023. URL: https://doi.org/10.3390/ijms24076754, doi:10.3390/ijms24076754. This article has 16 citations.

26. (owusuansah2023nagscps1and pages 1-2): Melissa Owusu-Ansah, Nikita Guptan, Dylon Alindogan, Michio Morizono, and Ljubica Caldovic. Nags, cps1, and slc25a13 (citrin) at the crossroads of arginine and pyrimidines metabolism in tumor cells. International Journal of Molecular Sciences, 24:6754, Apr 2023. URL: https://doi.org/10.3390/ijms24076754, doi:10.3390/ijms24076754. This article has 16 citations.

27. (nuyttens2025acrucialrole pages 2-3): Louise Nuyttens, Marah Heyerick, Maxime Roes, Elise Moens, Céline Van Dender, Charlotte Wallaeys, Tino Hochepied, Steven Timmermans, Jolien Vandewalle, and Claude Libert. A crucial role of the malate aspartate shuttle in metabolic reprogramming in tnf-induced sirs. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1652516, doi:10.3389/fimmu.2025.1652516. This article has 4 citations and is from a peer-reviewed journal.

28. (nuyttens2025acrucialrole pages 9-11): Louise Nuyttens, Marah Heyerick, Maxime Roes, Elise Moens, Céline Van Dender, Charlotte Wallaeys, Tino Hochepied, Steven Timmermans, Jolien Vandewalle, and Claude Libert. A crucial role of the malate aspartate shuttle in metabolic reprogramming in tnf-induced sirs. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1652516, doi:10.3389/fimmu.2025.1652516. This article has 4 citations and is from a peer-reviewed journal.

29. (nuyttens2025acrucialrole pages 11-12): Louise Nuyttens, Marah Heyerick, Maxime Roes, Elise Moens, Céline Van Dender, Charlotte Wallaeys, Tino Hochepied, Steven Timmermans, Jolien Vandewalle, and Claude Libert. A crucial role of the malate aspartate shuttle in metabolic reprogramming in tnf-induced sirs. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1652516, doi:10.3389/fimmu.2025.1652516. This article has 4 citations and is from a peer-reviewed journal.

30. (goyani2024calciumsignalingin pages 4-6): Shanikumar Goyani, Shatakshi Shukla, Pooja Jadiya, and Dhanendra Tomar. Calcium signaling in mitochondrial intermembrane space. Biochemical Society transactions, 52:2215-2229, Oct 2024. URL: https://doi.org/10.1042/bst20240319, doi:10.1042/bst20240319. This article has 11 citations and is from a peer-reviewed journal.

31. (kido2022clinicalmanifestationand pages 1-7): Jun Kido, Johannes Häberle, Keishin Sugawara, Toju Tanaka, Masayoshi Nagao, Takaaki Sawada, Yoichi Wada, Chikahiko Numakura, Kei Murayama, Yoriko Watanabe, Kanako Kojima‐Ishii, Hideo Sasai, Kiyotaka Kosugiyama, and Kimitoshi Nakamura. Clinical manifestation and long‐term outcome of citrin deficiency: report from a nationwide study in japan. Journal of Inherited Metabolic Disease, 45:431-444, Feb 2022. URL: https://doi.org/10.1002/jimd.12483, doi:10.1002/jimd.12483. This article has 39 citations and is from a peer-reviewed journal.

32. (hayasaka2024pathogenesisandmanagement pages 2-4): Kiyoshi Hayasaka. Pathogenesis and management of citrin deficiency. Internal Medicine, 63:1977-1986, Jul 2024. URL: https://doi.org/10.2169/internalmedicine.2595-23, doi:10.2169/internalmedicine.2595-23. This article has 18 citations and is from a peer-reviewed journal.

33. (haberle2024citrindeficiency—theeast‐side pages 1-2): Johannes Häberle. Citrin deficiency—the east‐side story. Journal of Inherited Metabolic Disease, 47:1129-1133, Jul 2024. URL: https://doi.org/10.1002/jimd.12772, doi:10.1002/jimd.12772. This article has 7 citations and is from a peer-reviewed journal.

34. (pardo2022agc1deficiencypathology pages 2-4): Beatriz Pardo, Eduardo Herrada-Soler, Jorgina Satrústegui, Laura Contreras, and Araceli del Arco. Agc1 deficiency: pathology and molecular and cellular mechanisms of the disease. International Journal of Molecular Sciences, 23:528, Jan 2022. URL: https://doi.org/10.3390/ijms23010528, doi:10.3390/ijms23010528. This article has 32 citations.

35. (gonzalezmoreno2023exogenousaralarslc25a12can pages 9-10): Luis González-Moreno, Andrea Santamaría-Cano, Alberto Paradela, María Luz Martínez-Chantar, Miguel Á. Martín, Mercedes Pérez-Carreras, Alberto García-Picazo, Jesús Vázquez, Enrique Calvo, Gloria González-Aseguinolaza, Takeyori Saheki, Araceli del Arco, Jorgina Satrústegui, and Laura Contreras. Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver. Jun 2023. URL: https://doi.org/10.1016/j.ymgmr.2023.100967, doi:10.1016/j.ymgmr.2023.100967. This article has 9 citations.

36. (rabinovich2020themitochondrialcarrier pages 2-4): Shiran Rabinovich, Alon Silberman, Lital Adler, Shani Agron, Smadar Levin-Zaidman, Amir Bahat, Ziv Porat, Efrat Ben-Zeev, Inbal Geva, Maxim Itkin, Sergey Malitsky, Adam Buchaklian, Daniel Helbling, David Dimmock, and Ayelet Erez. The mitochondrial carrier citrin plays a role in regulating cellular energy during carcinogenesis. Oncogene, 39:164-175, Aug 2020. URL: https://doi.org/10.1038/s41388-019-0976-2, doi:10.1038/s41388-019-0976-2. This article has 39 citations and is from a domain leading peer-reviewed journal.

37. (rabinovich2020themitochondrialcarrier pages 1-2): Shiran Rabinovich, Alon Silberman, Lital Adler, Shani Agron, Smadar Levin-Zaidman, Amir Bahat, Ziv Porat, Efrat Ben-Zeev, Inbal Geva, Maxim Itkin, Sergey Malitsky, Adam Buchaklian, Daniel Helbling, David Dimmock, and Ayelet Erez. The mitochondrial carrier citrin plays a role in regulating cellular energy during carcinogenesis. Oncogene, 39:164-175, Aug 2020. URL: https://doi.org/10.1038/s41388-019-0976-2, doi:10.1038/s41388-019-0976-2. This article has 39 citations and is from a domain leading peer-reviewed journal.

38. (rabinovich2020themitochondrialcarrier pages 4-5): Shiran Rabinovich, Alon Silberman, Lital Adler, Shani Agron, Smadar Levin-Zaidman, Amir Bahat, Ziv Porat, Efrat Ben-Zeev, Inbal Geva, Maxim Itkin, Sergey Malitsky, Adam Buchaklian, Daniel Helbling, David Dimmock, and Ayelet Erez. The mitochondrial carrier citrin plays a role in regulating cellular energy during carcinogenesis. Oncogene, 39:164-175, Aug 2020. URL: https://doi.org/10.1038/s41388-019-0976-2, doi:10.1038/s41388-019-0976-2. This article has 39 citations and is from a domain leading peer-reviewed journal.

39. (gao2024cancertherapeuticpotential pages 4-6): Renzhuo Gao, Dan Zhou, Xingpeng Qiu, Jiayi Zhang, Daya Luo, Xiaohong Yang, Caiyun Qian, and Zhuoqi Liu. Cancer therapeutic potential and prognostic value of the slc25 mitochondrial carrier family: a review. Cancer Control : Journal of the Moffitt Cancer Center, Jan 2024. URL: https://doi.org/10.1177/10732748241287905, doi:10.1177/10732748241287905. This article has 12 citations.

Artifacts

• Edison artifact artifact-00

Citations

1. kunji2025thepeculiarproperties pages 3-4
2. broeks2021inborndisordersof pages 6-10
3. lacabanne2025currentunderstandingof pages 3-4
4. tavoulari2024distinctrolesfor pages 11-12
5. tavoulari2024distinctrolesfor pages 9-11
6. contreras2010lowlevelsof pages 4-6
7. tavoulari2024distinctrolesfor pages 7-9
8. kido2022clinicalmanifestationand pages 7-11
9. komatsu2023citrindeficiencyclinical pages 1-2
10. kido2024clinicallandscapeof pages 1-2
11. vukovic2024thetherapeuticlandscape pages 1-2
12. rabinovich2020themitochondrialcarrier pages 4-5
13. palmieri2013themitochondrialtransporter pages 15-16
14. tavoulari2024distinctrolesfor pages 1-2
15. contreras2010lowlevelsof pages 1-2
16. lacabanne2025currentunderstandingof pages 4-6
17. ahmed2024theroleof pages 11-13
18. nuyttens2025acrucialrole pages 2-3
19. nuyttens2025acrucialrole pages 9-11
20. nuyttens2025acrucialrole pages 11-12
21. goyani2024calciumsignalingin pages 4-6
22. kido2022clinicalmanifestationand pages 1-7
23. hayasaka2024pathogenesisandmanagement pages 2-4
24. rabinovich2020themitochondrialcarrier pages 2-4
25. rabinovich2020themitochondrialcarrier pages 1-2
26. gao2024cancertherapeuticpotential pages 4-6
27. https://doi.org/10.1016/j.mam.2012.05.005,
28. https://doi.org/10.1016/j.molmet.2024.102047,
29. https://doi.org/10.1042/bcj20253171,
30. https://doi.org/10.1016/j.tibs.2019.11.001,
31. https://doi.org/10.1016/j.ymgmr.2023.100967,
32. https://doi.org/10.5483/bmbrep.2023-0052,
33. https://doi.org/10.1002/jimd.12768,
34. https://doi.org/10.1002/jimd.12722,
35. https://doi.org/10.1002/jimd.70021,
36. https://doi.org/10.1002/jnr.22283,
37. https://doi.org/10.1002/jimd.12402,
38. https://doi.org/10.3390/nu15102284,
39. https://doi.org/10.1002/jimd.12483,
40. https://doi.org/10.3390/ijms26010092,
41. https://doi.org/10.15252/embr.202050071,
42. https://doi.org/10.3390/ijms24076754,
43. https://doi.org/10.3389/fimmu.2025.1652516,
44. https://doi.org/10.1042/bst20240319,
45. https://doi.org/10.2169/internalmedicine.2595-23,
46. https://doi.org/10.1002/jimd.12772,
47. https://doi.org/10.3390/ijms23010528,
48. https://doi.org/10.1038/s41388-019-0976-2,
49. https://doi.org/10.1177/10732748241287905,